Screener
MapLight Therapeutics, Inc. MPLT Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 64,503 | 23,543 |
| Loss from operations | (64,503) | (23,543) |
| Other income, net: | ||
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
| Net loss | $(60,668) | $(22,340) |
| Net loss per share - basic and diluted | $(1.34) | $(29.33) |
| Weighted-average number of common shares outstanding - basic and diluted | 45,276,763 | 761,598 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s interest income?
- MapLight Therapeutics, Inc. (MPLT) reported interest income of $2.47M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s interest income changed year-over-year?
- MapLight Therapeutics, Inc.'s interest income increased by 204.8% year-over-year, from $811K to $2.47M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about MapLight Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude